EGFR G719A
|
NSCLC
|
EGFR G719A
|
NSCLC
|
gefitinib Sensitive: B - Late Trials
|
gefitinib Sensitive: B - Late Trials
|
EGFR G719A
|
NSCLC
|
EGFR G719A
|
NSCLC
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
EGFR G719A
|
NSCLC
|
EGFR G719A
|
NSCLC
|
dacomitinib Sensitive: C2 – Inclusion Criteria
|
dacomitinib Sensitive: C2 – Inclusion Criteria
|
EGFR G719A
|
NSCLC
|
EGFR G719A
|
NSCLC
|
osimertinib Sensitive: C3 – Early Trials
|
osimertinib Sensitive: C3 – Early Trials
|
EGFR G719A
|
NSCLC
|
EGFR G719A
|
NSCLC
|
sintilimab Sensitive: C3 – Early Trials
|
sintilimab Sensitive: C3 – Early Trials
|
EGFR G719A
|
NSCLC
|
EGFR G719A
|
NSCLC
|
amivantamab-vmjw Sensitive: C4 – Case Studies
|
amivantamab-vmjw Sensitive: C4 – Case Studies
|